Augmentation therapy in emphysema patient with ZZ α-1-antitrypsin deficiency

Respiratory Medicine CME

Volumn 1, Issue 2, 2008, Pages 153-157

  Sandström, Caroline S ^a   Piitulainen, Eeva ^a   Janciauskiene, Sabina ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

1 Antitrypsin deficiency; COPD; Neutrophils; Replacement therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIVER ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAMNESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CELL ISOLATION; CYTOKINE RELEASE; DRUG INFUSION; DRUG WITHDRAWAL; EMPHYSEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOELECTROPHORESIS; LUNG FUNCTION TEST; MALE; NEUTROPHIL; PRIORITY JOURNAL; RESIDUAL VOLUME; SPIROMETRY; STATISTICAL SIGNIFICANCE; TOTAL LUNG CAPACITY; TREATMENT DURATION; VITAL CAPACITY; WESTERN BLOTTING;

EID: 49149092839     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2008.03.007     Document Type: Article

References (21)

1. Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand 175 (1964) 197-205
2. Eriksson S., Carlson J., and Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314 (1986) 736-739
3. Lomas D.A., and Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 110 (2002) 1585-1590
4. Parfrey H., Mahadeva R., and Lomas D.A. Alpha(1)-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol 35 (2003) 1009-1014
5. Gadek J.E., Klein H.G., Holland P.V., et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 68 (1981) 1158-1165
6. Hubbard R.C., and Crystal R.G. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 84 (1988) 52-62
7. 1 decline in individuals with severe deficiency of alpha1-antitrypsin. The alpha-1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med 158 (1998) 49-59
8. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118 (2000) 1480-1485
9. Wencker M., Fuhrmann B., Banik N., et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 119 (2001) 737-744
10. Nita I., Hollander C., Westin U., et al. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 6 (2005) 12
11. Griese M., Latzin P., Kappler M., et al. alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 29 (2007) 240-250
12. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15 (1966) 45-52
13. Wallmark A., Alm R., and Eriksson S. Monoclonal antibody specific for the mutant PiZ alpha 1-antitrypsin and its application in an ELISA procedure for identification of PiZ gene carriers. Proc Natl Acad Sci USA 81 (1984) 5690-5693
14. Janciauskiene S., Zelvyte I., Jansson L., et al. Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro. Biochem Biophys Res Commun 315 (2004) 288-296
15. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with α-1 antitrypsin deficiency. Am J Respir Crit Care Med 168 (2003) 818-900
16. Dirksen A., Dijkman J.H., Madsen F., et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160 (1999) 1468-1472
17. Hubbard R.C., Brantly M.L., Sellers S.E., et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 111 (1989) 206-212
18. Hill A.T., Campbell E.J., Bayley D.L., et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 160 (1999) 1968-1975
19. Dowson L.J., Guest P.J., and Stockley R.A. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 164 (2001) 1805-1809
20. Tetley T.D. New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax 48 (1993) 560-565
21. Quint J.K., and Wedzicha J.A. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 119 (2007) 1065-1071